However, disease progression, as measured by the Hoehn and Yahr (HY) scale, is reported to be more rapid in patients with GBA1-associated PD and LRRK2-GBA1 dual mutation carriers than in those with mutation-negative PD (MNPD) [65]. This evidence concerns the gene LRRK2 and Parkinson disease.